Jiangsu Cell Tech Medical Research Institute (abbreviated as ELT or ELT Cell) is located in Jiangning High-tech Zone. ELT Cell was incorporated in August 2018, and has since evolved into an innovative R&D company based in Boston, USA, and Nanjing, China.

Our scientists and leadership had extensive working experiences in USA, Switzerland, Sweden, and China. Our publication and patenting records attest to the unique combination of drug discovery and development experiences at the ELT Cell. We are focused on developing technologies and products for unmet medical needs. Since the inception, ELT Cell has developed technology platforms such as TCR plus CAR for solid tumor treatment and long-acting biologicals for enhanced serum half-lives and increased tissue distributions. Our discovery pipelines include Hijack-Plus EDB TCR for cancer therapies, M164 as a regenerative medicine that treats endothelial and tissue injuries, and a version of long-acting follicle stimulating hormone that is best-in-class for treating infertilities.

ELT Cell is calling for international and domestic talents in medical and biotech arena to join our breakthrough research efforts and impact patient care.